Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
Alzheimer Disease - ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease
Antigenics Inc. - Antigenics Reports Second Quarter 2008 Financial Results
Ardea Biosciences, Inc. - Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Argos Therapeutics - Argos Therapeutics' Arcelis Personalized Immunotherapy Platform in HIV Achieves Primary Endpoint in Phase 1 Trial
ARIAD Pharmaceuticals, Inc. - ARIAD Announces Start of Phase 2 Clinical Study of Oral Deforolimus in Patients with Advanced Endometrial Cancer
Bionor Immuno - Bionor Immuno Advances HIV Peptide-Based Therapeutic Immunization Program with Start of a Phase IIb Trial in U.S. and Europe
Bioscience - David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
Biovest International, Inc. - Biovest Joins in the Formation of the Joint U.S.-Norway Cancer Research Program, a Collaborative Effort with Plans to Present to NCI and the U.S. Military Healthcare System
Cancer - Expression Genetics Inc., Specializing in DNA/RNAi Delivery and Therapeutics, Completes $12M Series B Financing
Cancer - Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
Cell Genesys, Inc. - Cell Genesys Reports Second Quarter 2008 Financial Results
Central Nervous System Disease - FDA Accepts Streamlined Phase 3 Development Plan for Q8003IR gDual Opioidh Pain Therapy
Clinical Trial Research - MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
Clinical Trial Research - Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
CombinatoRx, Incorporated - CombinatoRx to Present at the Canaccord Adams 28th Annual Global Growth Conference
Cortex Pharmaceuticals, Inc. - Cortex's AMPAKINE Molecule CX717 Has Positive Effects in Opiate-Induced Respiratory Depression in a Phase IIa Clinical Study
CPEX Pharmaceuticals, Inc. - CPEX Pharmaceuticals and Serenity Pharmaceuticals Announce Collaboration on Drug Candidate for Urology Indication
Depomed, Inc. - Depomed Reports Second Quarter 2008 Financial Results
Diabetes - InteKrin Therapeutics Announces $20 Million Series C Financing
DNA Vaccines - Vical Reports Second Quarter and First Six Months 2008 Financial Results and Highlights in Product Development Programs
Drug Development - Lilly Sells its Greenfield, Indiana, Operations to Covance; Expands Existing Collaboration Between the Two Companies
Dynavax Technologies Corporation - Dynavax and Merck & Co., Inc. Announce Phase 3 Trial with Investigational Hepatitis B Vaccine HEPLISAV Met its Primary Endpoint
Edema - Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
Emergent BioSolutions Inc. - Emergent BioSolutions Submits Proposal in Response to HHS RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine
Exelixis, Inc. - Exelixis Announces Second Quarter 2008 Financial Results
Genetics & Genomics - Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
Hepatitis C Virus - Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
HIV/AIDS - Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
Innocoll, Inc. - Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Life Sciences - Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.; New Company to be Called Kowa Pharmaceuticals America
MDRNA, Inc. - MDRNA Announces Phase 2 Trial of PYY3-36 Does not Meet Weight Loss Endpoint
MDRNA, Inc. - MDRNA, Inc. Announces Second Quarter 2008 Financial Results and Additional Corporate Restructuring
Medgenics, Inc. - Medgenics Granted Approval to Commence Its Landmark Phase I/II Clinical Study of EPODURE to Treat Anaemia
Menstruation - Xanodyne Achieves Positive Efficacy Results in Pivotal Phase 3 Studies of Proprietary Modified Release Oral Tranexamic Acid Product Candidate for Heavy Menstrual Bleeding
Merck & Co., Inc. - ISENTRESS raltegravir, Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naive HIV-Infected Patients When Taken With Other Anti
Monoclonal Antibodies - Panacea Pharmaceuticals Announces Appointment of Suzanne Sensabaugh as Vice President, Regulatory Affairs
Schering-Plough Corporation - Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response SVR in Genotype 1 Treatment-Naive Hepatitis C Patients
